Overview
TD Cowen has named BrightSpring Health Services Inc. (BTSG) its preferred mid-cap pick for 2026, reiterating the company’s leading position from the prior year while increasing the firm’s price target to $81 from $65. That new target represents roughly 27% upside from BrightSpring’s June 17, 2026 closing price of $64.43, and TD Cowen maintains a Buy recommendation.
Valuation and financial framework
The firm’s $81 projection derives from a five-year discounted cash flow analysis. Under TD Cowen’s framework the price target equates to approximately 19-20 times the firm’s 2027 adjusted EBITDA estimate, which it pegs at $998 million. TD Cowen frames the valuation in the context of BrightSpring’s stated operational objectives, noting the company has recently cleared the $10 billion market capitalization threshold and materially reduced leverage over the past year - developments the firm believes could catalyze additional institutional interest.
Operational thesis and growth drivers
TD Cowen highlights BrightSpring’s oncology-focused specialty pharmacy as a core asset and a key reason for its conviction. The analysis emphasizes the company’s footprint across high-growth vectors including oncology, specialty pharmaceuticals, and infusion services. Specific catalysts cited by the firm include wins for Limited Distribution Drugs, the introduction of specialty oncology generics, and a recovery and expansion in the infusion business.
TD Cowen identifies several product timing events that factor into its growth expectations: the firm lists an expected generic introduction for Pomalyst in 2026, followed by generic introductions for Ibrance and Xtandi in 2027. These product events are included among the drivers TD Cowen believes could help BrightSpring exceed its internal target for adjusted EBITDA growth of 15-20% through 2028.
Market activity and investor dynamics
In parallel coverage, Goldman Sachs has initiated analyst coverage on BrightSpring with a Buy rating and a $71 price target, citing accelerating momentum in the business. Separately, certain existing stockholders completed a secondary sale of 15 million common shares at $58.75 per share, with BrightSpring itself receiving no proceeds from that transaction.
Risk considerations
TD Cowen outlines a set of risks that could temper the investment thesis. A principal competitive risk is pressure from large pharmacy benefit managers that operate affiliated specialty pharmacies, which could intensify competition in the specialty pharmacy market. Another potential headwind is selling pressure associated with a substantial shareholder stake - KKR holds a 22% ownership position that TD Cowen flags as a potential source of market supply. Finally, the firm notes BrightSpring’s provider business is exposed to CMS rate decisions, which could materially affect reimbursement and revenue dynamics.
Context on expectations
TD Cowen’s forecast and price target are explicitly tied to the firm’s five-year cash flow projection and the 2027 adjusted EBITDA estimate. The combination of a raised price target, the Buy rating, and the specific operational catalysts cited underpin TD Cowen’s view that BrightSpring could outperform its near-term financial goals should the enumerated growth drivers materialize as expected.
Bottom line
TD Cowen’s 2026 mid-cap selection of BrightSpring centers on the company’s specialty oncology pharmacy, anticipated product-related catalysts, and an improving balance sheet. The firm’s $81 target and Buy rating reflect a valuation case built on a DCF model and a 2027 adjusted EBITDA estimate of $998 million, while also acknowledging competitive and ownership-related risks that could influence the stock’s performance.